Proton Therapy as a Bridging Treatment in CAR T-Cell Therapy for Relapsed and Refractory Large B-Cell Lymphoma: Is There a Role?

Omran Saifi, MD1; Mohamed A. Kharfan-Dabaja, MD, MBA2; Youssef H. Zeidan, MD, PhD3; Jennifer Peterson, MD4; William G. Rule, MD5; Scott C. Lester, MD6; Bradford S. Hoppe, MD, MPH4

1Faculty of Medicine, American University of Beirut, Beirut, Lebanon
2Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA
3Department of Radiation Oncology, American University of Beirut Medical Center, Beirut, Lebanon
4Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL, USA
5Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, USA
6Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Since the relapse rate of DLBCL to frontline chemoimmunotherapy and salvage autologous hematopoietic cell transplant is high, CD19-directed chimeric antigen receptor (CAR) T-cell therapy was adopted. Given the time interval needed for CAR T cells to be manufactured (3-5 weeks) and the aggressiveness of these relapsed/refractory lymphomas, some patients do not make it to the CAR T-cell infusion phase. This calls for a bridging therapy to control, debulk, and sensitize the disease during this period. Radiation therapy can serve this purpose and has shown promising results in some studies. Proton therapy, compared to standard radiation therapy, in some locations, can reduce the radiation dose to the organs at risk, which may lead to fewer side effects for patients with lymphomas. Thus, we hypothesize that proton therapy may serve as a promising bridging strategy to CAR T-cell therapy for some patients.

Keywords: CAR T-cell therapy; proton therapy; bridging therapy; non-Hodgkin lymphoma

Introduction

Non-Hodgkin lymphoma is the most common hematologic malignancy [1]. It accounts for 4.3% of all cancers in the United States, ranked as the seventh most common cancer among males and the sixth among females [2]. Among all non-Hodgkin lymphoma subtypes, diffuse large B-cell lymphoma (DLBCL) is the most common, accounting for 30% to 40% of all cases [3]. Main frontline treatment for DLBCL includes chemoimmunotherapy with/without radiation therapy. Up to 90% of patients achieve an objective response after frontline treatment with anthracycline-based chemoimmunotherapy combining cyclophosphamide, vincristine, doxorubicin, and prednisone and the anti-CD20 monoclonal antibody rituximab (R-CHOP); of these 10% to 30% will relapse [4, 5].

The standard salvage therapy includes second-line chemotherapy followed by high-dose chemotherapy and autologous hematopoietic cell transplant (auto-HCT) [6], with relapse rates of approximately 20% to 50% or higher in patients with complete metabolic
response versus those attaining a partial metabolic response or less as assessed by positron emission tomography–computed tomography to second-line chemotherapy [7].

No standard therapy exists for patients who have relapse following auto-HCT or after failure of 2 or more lines of therapies in transplant-ineligible cases [8]. Depending on a number of factors, patients may receive third-line chemotherapy, targeted therapy, allogeneic HCT, and most recently CD19-directed chimeric antigen receptor (CAR) T-cell therapy, which have demonstrated objective response rate of 52% to 82%, and complete remission of 40% to 52% [9–11].

Radiation therapy has also been an effective treatment of DLBCL during the past century. Initially it was viewed as a palliative treatment modality for DLBCL, then later as a potentially curative treatment before the widespread use of chemotherapy. Currently it plays important roles in consolidation of first-line therapy and peritransplant treatments [4, 12, 13]. Recently, radiation has been considered as a bridging strategy to CAR T-cell therapy to debulk tumor burden, preserve performance status, and achieve the needed lymphodepletion until the CAR T cells are manufactured and ready to be infused [14, 15]. Multiple forms of radiation therapy are commonly used to treat lymphoma, including electrons, photons, and protons. Of these, proton therapy has the greatest potential to reduce collateral radiation to uninvolved organs [16]. In this review, we provide an overview of CAR T-cell therapy in relapsed DLBCL and discuss the possible role of proton therapy as a bridging tool for CAR T-cell therapy.

Role of CAR T-Cell Therapy in the Treatment of Relapsed DLBCL

Currently, CAR T-cell therapy is indicated for large B-cell lymphoma that fails 2 or more lines of therapies. CAR T-cell therapy is an autologous cellular immunotherapy that uses the patient’s own T lymphocytes and genetically reengineers them to recognize and attack cancerous cells. CD19 glycoprotein is uniformly expressed in all stages of B-cell maturation and is expressed in more than 95% of B-cell malignancies [17], which makes it an ideal target for CAR T cells to recognize. CAR T cells have additional activation and recognition domains that allow them to expand and proliferate [18]. First-generation CAR T cells showed limited antitumor activity owing to weak proliferation and persistence [19]. Consequently, costimulatory domains were added to second-generation CAR T cells, which significantly improved proliferation, persistence, and signaling strength [20]. The most commonly used costimulatory domains are CD28 and 41BB.

The CAR T-cell manufacturing process starts with leukapheresis, the harvesting of the patient’s own lymphocytes. Subsequently, T cells are transfected with a replication-defective virus (lentivirus or retrovirus) that holds the CAR gene. CAR T cells are then expanded in vitro and infused back to the patient approximately 3 weeks later [21, 22]. A lymphodepleting chemotherapy regimen is commonly prescribed a few days before infusing the CAR T cells to facilitate homeostatic cell proliferation. Fludarabine and cyclophosphamide chemotherapy is the most commonly prescribed combination therapy for such purpose [23]; however, the JULIET study also allowed bendamustine for 2 days [10]. Regrettably, one of the main issues with this treatment approach is the length of time to infusion of the CAR T-cell therapy, which provides time for the DLBCL to progress; as a result, in the ZUMA-1 trial, approximately 10% of patients did not end up receiving the CAR-T product [11]. Therefore, different treatment approaches have been developed to try to control the lymphoma during the manufacturing phase, or provide a “bridging treatment” until the CAR T-cell infusion.

The 2 CAR T-cell therapies that are US Food and Drug Administration approved for the treatment of relapsed and/or refractory (R/R) large B-cell lymphoma are axicabtagene cileoleucel (axi-cel) and tisagenlecleucel (tisa-cel), which have CD28 and CD41BB as costimulatory domains, respectively. Axi-cel proved effective for the treatment of R/R large B-cell lymphoma in the ZUMA-1 trial, showing a 1-year objective response rate and complete remission of 82% and 54%, respectively, and progression-free survival of 41% at 15 months. No bridging therapy was allowed, and lymphodepletion followed a 3-day course of fludarabine and cyclophosphamide [9, 24]. Similarly, tisa-cel proved effective in the JULIET trial, achieving a best overall response rate of 52% and 1-year relapse-free survival rate of 65%. Ninety percent of patients in this trial received bridging therapy (54% received rituximab, and 40% received gemcitabine), and 93% received lymphodepleting chemotherapy with either fludarabine and cyclophosphamide, or bendamustine [10].

CAR T-cell therapy brings a new array of toxicities, and several studies have described these side effects [25, 26]. To date, the most concerning are cytokine release syndrome (CRS) and neurotoxicity. Depending on the prescribed product, incidence of CRS ranges from 50% to 93% [10, 11, 27] and is purportedly due to the excessive release of cytokines as CAR T cells expand, proliferate, and attack lymphoma cells. This might be more prominent in the presence of bulky and extensive disease as seen with high leukemia burden [28, 29]. The incidence of neurotoxicity also varies depending on the prescribed product, with reported incidence (any grade) of approximately 20% with tisa-cel and up to 64% with axi-cel [10, 11] and is thought to
result from the ability of the CAR T cells to cross the blood-brain barrier, causing inflammation in the central nervous system. Although CRS can be managed with tocilizumab (anti–interleukin 6 receptor) and siltuximab (anti–interleukin 6 antibody), it is critical enough and may require admission and observation in the intensive care unit in the presence of serious compromise of organ function. Neurotoxicity is generally treated with corticosteroids; however, high-grade neurotoxicity may require aggressive interventions, including airway protection [30].

Role of Radiation Therapy in the Treatment of DLBCL

Radiation therapy is an effective treatment for DLBCL as consolidation treatment following chemotherapy in early stage [31] and for patients with bulky disease [32, 33]. Moreover, radiation plays a role in achieving local control in some cases with relapsed DLBCL that become refractory to chemotherapy and stem cell transplant [4, 12, 34, 35]. On the other hand, radiation therapy for lymphoma can have acute and long-term toxicities. While acute toxicities are generally mild and can include hematologic suppression, dermatitis, mucositis, esophagitis, nausea, diarrhea, fatigue, and/or constipation, the late effects can be more significant and include cardiac toxicity, pulmonary fibrosis, and second malignancies. New strategies have been developed to reduce radiation toxicity, including decreasing the radiation dose and field size, using modern radiation therapy techniques, such as intensity-modulated radiation therapy (IMRT), and using proton therapy. International Lymphoma Radiation Oncology Group (ILROG) developed standard involved site radiation therapy guidelines for nodal and extranodal lymphomas, which are generally smaller than the previously used involved-field radiation therapy guidelines [36, 37]. Proton therapy is highly conformal, allowing it to target the disease site while sparing nearby healthy tissues. While the data are limited for the use of protons in the treatment of DLBCL, some studies have shown promising outcomes with minimal toxicity. Sachsman et al [38] reported a 91% 2-year local control rate and no grade 3 or 4 radiation toxicities for patients with DLBCL treated with proton therapy, during the 38-month follow-up period. Plastaras et al [39] reported on 24 patients with primary mediastinal B-cell lymphoma treated with proton therapy and demonstrated only 1 local relapse.

Radiation Therapy as a Bridging Tool for CAR T-Cell Therapy

CAR T-cell therapy and radiation therapy can benefit patients with relapsed DLBCL; combining the two might yield promising results [15]. In fact, radiation therapy could serve as a successful bridging strategy for CAR T-cell therapy by several means: (1) Aggressive relapsed lymphomas are usually refractory to systemic therapy and may progress during CAR T-cell manufacturing (2-6 weeks), weakening the patient and reducing the response to CAR T-cell therapy as seen in the ZUMA-1 trial where approximately 10% of the patients did not receive the CAR-T product owing to disease progression among other reasons [11]. However, even chemoresistant lymphomas can demonstrate sensitivity to radiation [40], which can be used to control the disease during manufacturing. (2) Radiation can serve solely or in combination with chemotherapy as a lymphodepleting agent giving CAR T cells the needed space to work. (3) Radiation has been proven to sensitize solid tumors to immunotherapy [41, 42] and more recently, to provoke an abscopal-like effect to CAR T-cell therapy [43], suggesting its ability to enhance CAR T-cell activity. (4) Radiation can decrease the lymphoma tumor burden, which in turn may potentially decrease the cytokines released after the infusion of CAR T cells. This could, parenthetically, reduce the severity of CRS [28, 29, 44] and hence reduce the need for higher doses of steroids, which have lympholytic properties. (5) Some CAR T-cell candidates may have indications for radiation therapy. These include those that have symptomatically involved sites that need palliation, bulky disease, and limited area of relapsed lymphoma that can be encompassed in radiation fields. Radiation in these patients can serve a dual purpose.

Arscott et al [45] were the first to report the use of radiation as a bridge to CAR T-cell therapy. Five patients were bridged with radiation before tisa-cel infusion. They reported no grade 3 or higher CRS in those patients. Moreover, the 1-year progression-free survival among the patients who received radiation was better (78%) than among those who did not receive radiation (44%). Sim et al [46] bridged 12 patients with radiation before axi-cel infusion. They reported that 80% of the patients responded to radiation, and none had significant toxicities during bridging. Moreover, none had disease progression before CAR T-cell infusion [46]. Imber et al [47] reported as well excellent pre CAR local control and initial post CAR objective response rate (100%) after bridging 11 DLBCL patients with radiation. LaRiviere et al [44] prescribed bridging radiation therapy to 5 patients before CAR T-cell infusion. None of these patients developed grade 3 or higher CRS compared to 5 of 19 who did not receive prior radiation. There were no reported deaths (0 of 5) after 139 days of follow-up. Disease progression was seen in 2 of 5 patients who received radiation induction as compared to 10 of 19 who did not receive induction [44] (Table).
Since one of the main adverse events radiation can cause in these patients is blood dyscrasia [48], it is advised to perform apheresis before radiation to avoid lymphopenia. Data suggest lower success rates of CAR T-cell manufacturing with lower absolute lymphocyte count (generally defined as fewer than 100/\(\mu\)L) [49]. On the other hand, hematologic toxicity from radiation can be leveraged to help in lymphodepletion following the apheresis.

### Role for Proton Therapy

To date no studies have reported the use of proton therapy as a bridging strategy to CAR T-cell therapy. As previously described, standard radiation therapy using photons may help to decrease CAR T-cell therapy–related toxicities and, thus far, has been associated with low rates of radiation-related toxicity. However, in some situations, based on disease distribution (eg, mediastinal involvement) and radiation dose, patients could be at risk of radiation-related toxicities such as pneumonitis [50], colitis, esophagitis, mucositis, and xerostomia that might cause the patient or physician to decline such treatment. In fact, the ILROG report on proton therapy for mediastinal lymphomas recommends consideration of proton therapy for “heavily pretreated patients who are at higher risk for radiation-related toxicity to the bone marrow, heart, and lungs [51].” Unfortunately, it is not clear why so few patients receive radiation therapy as bridging treatment to CAR T-cell therapy and we can only hypothesize that fear of radiation therapy toxicity may contribute. In that scenario, proton therapy can be used to reduce the radiation dose to the organs at risk for patients with lymphomas, yielding similar disease outcomes, though potentially with fewer side effects than photon-based radiation therapy [38, 52]. This may be more critical for those with disease located in the mediastinal region, where pneumonitis could be a significant factor.

Additionally, lymphopenia can occur following radiation therapy, and lymphopenia has been shown to be a prognostic factor for successful collection and manufacturing of CAR T cells. Avoiding radiation therapy before leukapheresis of T cells is strongly encouraged. If radiation is needed urgently before leukapheresis, proton therapy may reduce the impact on absolute lymphocyte count. Among patients with esophageal cancer and lung cancer receiving radiation therapy, lymphopenia occurs less often with proton therapy than with IMRT [53, 54]. Since protons have similar control rates with the potential for reduced side effects, compared to other forms of radiation therapy, the use of protons as a bridging strategy for CAR T-cell therapy may reduce side effects, augment response, or both. Future trials and studies are needed to validate this hypothesis.

While proton therapy may offer some hypothetical benefit for patients, it may also be inferior in some ways. As previously mentioned, IMRT may contribute more to lymphopenia, which may actually be helpful during manufacturing in an effort to make room for eventual CAR T-cell infusion. Additionally, proton therapy could contribute to the rising cost of treatment, which is already quite substantial with CAR T-cell treatment [55]. Therefore, careful exploration for using proton therapy in CAR T-cell treatment is needed, such as on a clinical trial or registry [56].

### Conclusion

CAR T-cell therapy represents one of the most innovative and revolutionary treatments for R/R large B-cell lymphoma. Using radiation therapy as a bridging technique could reduce CAR T-cell therapy–related toxicity and increase the number of patients that will reach the infusion phase of treatment. This is due to the ability of radiation to lymphodeplete, cy toreduce, debulk, stabilize, and sensitize the tumor. Proton therapy can serve as an alternative to the standard radiation therapy to further minimize radiation-related toxicities, making it a promising bridging strategy for CAR T-cell therapy in DLBCL for some patients.
Addition Information and Declarations

Conflicts of Interest: The authors have no relevant conflicts of interest to disclose.

References

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*. 2015;136:E359–86.

2. Chihara D, Nastoupil LJ, Williams JN, Lee P, Koff JL, Flowers CR. New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy. *Expert Rev Anticancer Ther*. 2015;15:531–44.

3. Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. *Blood*. 2015;125:22–32.

4. Ng AK, Yahalom J, Goda JS, Constine LS, Pinnix CC, Kelsey CR, Hoppe B, Oguchi M, Suh CO, Wirth A, Qi S, Davies A, Moskowitz CH, Laskar S, Li Y, Mauch PM, Specht L, Illidge T. Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. *Int J Radiat Oncol Biol Phys*. 2018;100:652–69.

5. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. *N Engl J Med*. 2002;346:235–42.

6. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Leelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. *N Engl J Med*. 1995;333:1540–5.

7. Sauter CS, Matasar MJ, Meikle J, Schoder H, Ulaner GA, Migliacci JC, Hilden P, Devlin SM, Zelenetz AD, Moskowitz CH. Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. *Blood*. 2015;125:2579–81.

8. Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L, Boussetta S, Feng L, Maurer MJ, Navale L, Wiezorek J, Go WY, Gisselbrecht C. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. *Blood*. 2017;130:1800–8.

9. Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunischweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. *Lancet Oncol*. 2019;20:31–41.

10. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jager U, Jaglowski S, Andreacis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacauda LB, Awasthi R, Chu J, Anak O, Salles G, Maziarz RT. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. *N Engl J Med*. 2017;377:2531–44.

11. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunischweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. *N Engl J Med*. 2017;377:2531–44.

12. Hoppe BS, Moskowitz CH, Filippa DA, Moskowitz CS, Kewalramani T, Zelenetz AD, Yahalom J. Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity. *J Clin Oncol*. 2008;26:1858–64.

13. Biswas T, Dhakal S, Chen R, Hyrien O, Bernstein S, Friedberg JW, Fisher RI, Liesveld J, Phillips G, Constine LS. Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era. *Int J Radiat Oncol Biol Phys*. 2010;77:79–85.

14. Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak O, Brogdon JL, Pruteanu-Malinici I, Bhog V, Landsburg D, Wasik M, Levine BL, Lacey SF, Melenhorst JJ, Porter DL, June CH. Chimeric antigen receptor T cells in refractory B-cell lymphomas. *N Engl J Med*. 2017;377:2545–54.
15. Dreyfuss AD, Lariviere M, Ballas LK, Plastaras JP. CAR-T cell therapy for lymphoma: how does radiation therapy fit in [published online ahead of print September 28, 2019]. Pract Radiat Oncol. 2019. doi:10.1016/j.prro.2019.09.010.

16. Lautenschlaeger S, Ianca G, Flattén V, Baumann K, Thiemer M, Dumke C, Zink K, Hauswald H, Vordermark D, Mauz-Korholz C, Engenhart-Cabillic R, Eberle F. Advantage of proton-radiotherapy for pediatric patients and adolescents with Hodgkin’s disease. Radiat Oncol. 2019;14:157.

17. Scheuermann RH, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma. 1995;18:385–97.

18. Chavez JC, Bachmeier C, Kharfan-Dabaja MA. CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. Ther Adv Hematol. 2019;10:2040620719841581.

19. Brocker T, Karjalainen K. Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. J Exp Med. 1995;181:1653–9.

20. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, Kamble RT, Bollard CM, Gee AP, Mei Z, Liu H, Grilley B, Rooney CM, Heslop HE, Brenner MK, Dotti G. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011;121:1822–6.

21. Kochenderfer JN, Feldman SA, Zhao Y, Xu H, Black MA, Morgan RA, Wilson WH, Rosenberg SA. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother. 2009;32:689–702.

22. Wang X, Riviere I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncolytics. 2016;3:16015.

23. Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, Hwang LN, Yu Z, Wrzesinski C, Heimann DM, Surrh CD, Rosenberg SA, Restifo NP. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med. 2005;202:907–12.

24. Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, Ghobadi A, Budde LE, Bot A, Rossi JM, Jiang Y, Xue AX, Elias M, Aycock J, Wiezorek J, Go WY. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther. 2017;25:285–95.

25. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, Raffeld M, Feldman S, Lu L, Li YF, Ngo LT, Goy A, Feldman T, Spaner DE, Wang ML, Chen CC, Kranick SM, Nath A, Nathan DA, Morton KE, Toomey MA, Rosenberg SA. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33:540–9.

26. Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, Hawkins R, Chaney C, Cherian S, Chen X, Soma L, Wood B, Li D, Heimfeld S, Riddell SR, Maloney DG. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8:355ra116.

27. Murthy H, Iqbal M, Chavez JC, Kharfan-Dabaja MA. Cytokine release syndrome: current perspectives. Immunotargets Ther. 2019;8:43–52.

28. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rilling R, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–17.

29. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stoneck D, Tschemeria N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne AS, Mackall CL. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385:517–28.

30. Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldjerou L, Gardner RA, Frey N, Curran KJ, Pegg K, Pasquini M, DiPersio JF, van den Brink MR, Komanduri KV, Grupp SA, Neelapu SS. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625–38.

31. Miller TP, Dahlberg S, Cassidy JR, Adelstein DJ, Spier CM, Grogan TM, LeBlanc M, Carlin S, Chase E, Fisher RI. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med. 1998;339:21–6.
32. Lamy T, Damaj G, Soubeyran P, Gyan E, Cartron G, Bouabdallah K, Gressin R, Cornillon J, Banos A, Le Du K, Benchalal M, Moles MP, Le Gouill S, Fleury J, Godmer P, Maisonneuve H, Deconinck E, Houot R, Laribi K, Marolleau JP, Tournilhac O, Branger B, Devillers A, Vuillez JP, Fest T, Colombat P, Costes V, Szablewski V, Bene MC, Delwail V. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. *Blood*. 2018;131:174–81.

33. Held G, Murawski N, Ziepert M, Fleckenstein J, Poschel V, Zwick C, Bittenbring J, Hanel M, Wilhelm S, Schubert J, Schmitz N, Loffler M, Rube C, Pfleulschuh M. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. *J Clin Oncol*. 2014;32:1112–8.

34. Tseng YD, Chen YH, Catalano PJ, Ng A. Rates and durability of response to salvage radiation therapy among patients with refractory or relapsed aggressive non-Hodgkin lymphoma. *Int J Radiat Oncol Biol Phys*. 2015;91:223–31.

35. Hoppe BS, Moskowitz CH, Zhang Z, Maragulia JC, Rice RD, Reiner AS, Hamlin PA, Zelenetz AD, Yahalom J. The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma. *Bone Marrow Transplant*. 2009;43:941–8.

36. Yahalom J, Illidge T, Specht L, Hoppe RT, Li YX, Tsang R, Wirth A. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. *Int J Radiat Oncol Biol Phys*. 2015;92:11–31.

37. Illidge T, Specht L, Yahalom J, Aleman B, Berthelsen AK, Constine L, Dabanua B, Dharmarajan K, Ng A, Ricardi U, Wirth A. Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. *Int J Radiat Oncol Biol Phys*. 2014;89:49–58.

38. Sachsman S, Flampouri S, Li Z, Lynch J, Mendenhall NP, Hoppe BS. Proton therapy in the management of non-Hodgkin lymphoma. *Leuk Lymphoma*. 2015;56:2608–12.

39. Plastaras JP, Maity A, Flampouri S, Miller D, Mendenhall NP, Svoboda J, Landsburg DJ, Hoppe BS. Bi-institutional report on consolidative proton therapy after initial chemotherapy for mediastinal diffuse large B-cell and primary mediastinal large B-cell lymphomas. *Int J Radiat Oncol Biol Phys*. 2018;102:e350.

40. Martens C, Hodgson DC, Wells WA, Sun A, Bezkaj A, Pintilie M, Crump M, Gospodarowicz MK, Tsang R. Outcome of hyperfractionated radiotherapy in chemotheraphy-resistant non-Hodgkin’s lymphoma. *Int J Radiat Oncol Biol Phys*. 2006;64:1183–7.

41. DeSelm C, Palomba ML, Yahalom J, Hamieh M, Eyquem J, Rajasekhar VK, Sadelan M. Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape. *Mol Ther*. 2018;26:2542–52.

42. Weiss T, Weller M, Guckenberger M, Sentman CL, Roth P. NKG2D-based CAR T cells and radiotherapy exert synergistic efficacy in glioblastoma. *Cancer Res*. 2018;78:1031–43.

43. Smith EL, Mailankody S, Staehr M. BCMA-targeted CAR T-cell therapy plus radiotherapy for the treatment of refractory myeloma reveals potential synergy. *Cancer Immunol Res*. 2019;7:1047–53.

44. LaRiviere MJ, Wright CM, Arscott WT, Miller D, Weber E, Landsburg DJ, Svoboda J, Nasta SD, Gerson JN, Chong EA, Schuster S, Maity A, Plastaras JP. Induction radiation prior to commercial chimeric antigen receptor T-cell therapy for relapsed/refractory non-Hodgkin lymphoma. *Int J Radiat Oncol Biol Phys*. 2019;105:S66.

45. Arscott WT, Miller D, Jones JA, Winchell N, Schuster S, Plastaras JP. Tandem induction radiation and chimeric antigen receptor T cell therapy in patients with relapsed or refractory non-Hodgkin lymphoma. *Int J Radiat Oncol Biol Phys*. 2018;102:S122.

46. Sim AJ, Jain MD, Figura NB, Chavez JC, Shah BD, Khimani F, Lazaryan A, Krivenko G, Davila ML, Liu HD, Falchook AD, Dahiya S, Rapoport AP, Kim S, Locke FL, Robinson TJ. Radiation therapy as a bridging strategy for CAR T cell therapy with axicabtagene ciloleucel in diffuse large B-cell lymphoma. *Int J Radiat Oncol Biol Phys*. 2019;105:1012–21.

47. Imber BS, Palomba ML, DeSelm C, Batlevi C, Dahi PB, Giralt S, Noy AM, Park JH, Sauter CS, Scordo M, Shah G, Sadelan M, Perales M, Yahalom J. MSKCC early experience using radiotherapy as a bridging strategy for relapsed diffuse large B cellular lymphoma before CD19 CAR T therapy. *Hematol Oncol*. 2019;37:259–61.

48. Colosia A, Njue A, Trask PC, Olivares R, Khan S, Abbe A, Police R, Wang J, Ruiz-Soto R, Kaye JA, Awan F. Clinical efficacy and safety in relapsed/refractory diffuse large B-cell lymphoma: a systematic literature review. *Clin Lymphoma Myeloma Leuk*. 2014;14:343–55.e6.
49. Davis MM, Fesnak A, Leskowitz RM, McKee JS, Ohayon Y, Corl CM, Malakhin A, Fraietta JA, Joseph Melenhorst J, June C, Schuster S, Levine BL. Predictors of manufacturing (MFG) success for chimeric antigen receptor (CAR) T cells in non-Hodgkin lymphoma (NHL). *Cytotherapy*. 2017;19:S118–9.

50. Pinnix CC, Smith GL, Milgrom S, Osborne EM, Reddy JP, Akhtari M, Reed V, Arzu I, Allen PK, Wogan CF, Fanale MA, Oki Y, Turturro F, Romaguera J, Fayad L, Fowler N, Westin J, Nastoupil L, Hagemeister FB, Rodriguez MA, Ahmed S, Nieto Y, Dabaja B. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma. *Int J Radiat Oncol Biol Phys*. 2015;92:175–82.

51. Dabaja BS, Hoppe BS, Plastaras JP, Newhauser W, Rosolova K, Flampouri S, Mohan R, Mikhaeel NG, Kirova Y, Specht L, Yahalom J. Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines. *Blood*. 2018;132:1635–46.

52. Tseng YD, Cutter DJ, Plastaras JP, Parikh RR, Cahlon O, Chuong MD, Dedeckova K, Khan MK, Lin SY, McGee LA, Shen EY, Terezakis SA, Badiyan SN, Kirova YM, Hoppe RT, Mendenhall NP, Pankuch M, Flampouri S, Ricardi U, Hoppe BS. Evidence-based review on the use of proton therapy in lymphoma from the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee. *Int J Radiat Oncol Biol Phys*. 2017;99:825–42.

53. Routman DM, Garant A, Lester SC, Day CN, Harmsen WS, Sanheuza CT, Yoon HH, Neben-Wittich MA, Martenson JA, Haddock MG, Hallemier CL, Merrell KW. A comparison of grade 4 lymphopenia with proton versus photon radiation therapy for esophageal cancer. *Adv Radiat Oncol*. 2019;4:63–9.

54. Fang P, Shiraishi Y, Verma V, Jiang W, Song J, Hobbs BP, Lin SH. Lymphocyte-sparing effect of proton therapy in patients with esophageal cancer treated with definitive chemoradiation. *Int J Particle Ther*. 2018;4:23–32.

55. Harkins RA, Patel SP, Flowers CR. Cost burden of diffuse large B-cell lymphoma. *Expert Rev Pharmacoecon Outcomes Res*. 2019;19:645–61.

56. Hoppe BS, Tsai H, Larson G, Laramore GE, Vargas C, Tseng YD, Dunn M, McGee L, Cahlon O, Hartsell W. Proton therapy patterns-of-care and early outcomes for Hodgkin lymphoma: results from the Proton Collaborative Group Registry. *Acta Oncol*. 2016;55:1378–80.